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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity
and mortality. Early detection and appropriate treatment and management of COPD can
lower morbidity and perhaps mortality. Clinicians in the primary care setting provide the
majority of COPD care and are pivotal in the diagnosis and management of COPD. In this
review, we provide an overview of the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2020 report, with a focus on the management of COPD in the primary
care setting. We discuss the pathophysiology of COPD; describe COPD risk factors, signs,
and symptoms that may facilitate earlier diagnosis of COPD; and reinforce the importance of
spirometry use in establishing the diagnosis of COPD. Disease monitoring, as well as
a review of the 2020 GOLD treatment recommendations, is also discussed. Patients and
families are important partners in COPD management; therefore, we outline simple steps that
may assist them in caring for those affected by COPD. Finally, we discuss nonpharmacolo
gical treatment options for COPD, COPD monitoring tools that may aid in the evaluation of
disease progression and response to therapy, and the importance of developing a COPD
action plan on an individualized basis.
Keywords: COPD, LABA, LAMA, primary care
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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and
mortality. COPD is the seventh leading cause of years of life lost globally, and lower
respiratory disease is the fourth leading cause of death in the United States.1,2 In the
United States, the age-standardized COPD-related death rate was 39.1 deaths per
100,000 in 2014 (44.3 in men and 35.6 in women per 100,000).3 COPD symptoms
can be debilitating and prevent patients and their families from leading normal lives.
Because of breathlessness, the level of daily physical activity is typically lower in
patients with COPD than in healthy controls.4 Additionally, patients with COPD often
have comorbidities such as anxiety, depression, osteoporosis, and cardiovascular
disease,5 which further impact their overall health, quality of life (QoL), functional
status, and clinical outcomes. COPD is also associated with substantial socioeconomic
impact, with high direct and indirect costs—estimated at $36 billion annually—bur
dening the health care system.6 Direct costs predominantly result from exacerbations
leading to emergency department (ED) visits, hospital admissions and readmissions,
and unscheduled office visits.6,7 Clearly, COPD impacts not only patients but also the
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society as a whole and this impact can be reduced with early
identification and appropriate treatment and management.8,9
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) report includes recommended strategies
for the diagnosis, treatment, and management of COPD.5
The COPD Foundation (COPDF) also provides a brief,
point-of-care pocket consultant guide that serves as
a short summary to aid clinical decision-making during
office, ED, or hospital visits.10 In this review, we provide
an overview of the GOLD 2020 report, with a focus on
recommendations for the treatment and management of
COPD in the primary care setting.

Pathophysiology of COPD
COPD results from chronic inflammation of the airways,
which leads to thickening of airway walls, increased
mucus production, and eventually permanent changes in
lung structure11 (Figure 1). Lung changes may include the
destruction of lung parenchyma including air sac (alveo
lar) walls, resulting in fibrosis of the small airways
(emphysema) and loss of elasticity.12 These structural
changes may cause increased resistance to airflow, signifi
cant air trapping, and ultimately hyperinflation, all of
which may manifest as breathlessness, cough, and
increased phlegm production.11
Chronic lung inflammation in COPD is generally char
acterized by increased neutrophils, activated macrophages,
and activated CD8+ T lymphocytes.12 The predominant
increase in types of inflammatory cells differs between
COPD and asthma (Table 1).12 Macrophages facilitate
the recruitment of other inflammatory cells (such as neu
trophils) and the release of mediators and proteases, which
may lead to emphysema.13 A subset of COPD patients
have predominant eosinophilic inflammation even in the
absence of exacerbations.14
Patients and families require accurate but simple explana
tions of COPD pathophysiology that can help them understand
this chronic condition, its symptoms, and recommended phar
macological and nonpharmacological therapies. For example,
when discussing dyspnea or shortness of breath, clinicians can
explain that patients with even mild-to-moderate COPD can
inhale a high volume of air (approaching total lung capacity).
However, they may be able to exhale only a portion of the
inhaled volume, resulting in air trapping and hyperinflation.15
As patients breathe more rapidly (eg, during exercise), they
have even shorter time for exhalation and, less and less “room”
to breathe in (ie progressively increased end-expiratory lung
volume and decreased inspiratory capacity), both of which
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Figure 1 Pathophysiology of chronic obstructive pulmonary disease. During the
time course of COPD, inflammation of the airways can lead to thickening of the
airway walls, increased mucus production, and damage to alveoli and alveolar ducts
that leads to enlargement of the air spaces/emphysema, and potentially to airtrapping.11

enhance dyspnea or shortness of breath because of inability
to “get air in.” This phenomenon can be illustrated by asking
the patient to take a deep breath in, exhale only a small amount
of the breath (air trapping), and then attempt to take in three
quick breaths. The patient will experience acute dyspnea and
discomfort, as they will have more difficulty with inhalation
because of residual air in the lungs (ie hyperinflation). This
maneuver mimics what happens with hyperinflation during
rest (static hyperinflation) and also during increased activity
(dynamic hyperinflation) when the respiratory rate is faster.15
Exertion leaves less time to exhale and, consequently no room
to let new air in. Common descriptors of air trapping, which
are important to know to understand patients’ experiences and
estimating disease severity, include “air hunger,” “unsatisfied”
or “unrewarded” inhalation, “shallow breathing,” “suffocat
ing,” and “cannot get a deep breath.”15,16

Patient Presentation
Patients with COPD commonly present with dyspnea,
chronic cough, and/or sputum production, and occasionally
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Table 1 Differences Between
Pathophysiology and Symptoms

COPD

and

Asthma

COPD

Asthma

Neutrophils
Eosinophils (mild

Eosinophils
(degranulated) CD4+,

elevation, not

CD3+, CD25+, and

degranulated)
CD8+, CD3+, CD68+,

CD45+ T cells
Mast cells

CD45+, VLA-1+, and

Macrophages

Pathologic changes
Inflammatory
cells

HLA-DR+ T cells
Macrophages
Bronchial

Enlarged mass in small

Enlarged mass in large

smooth muscle

airways

airways

Mucus

Present, heavy

Present

secretion
Clinical presentation
Symptoms

Allergic

Progressive dyspnea

Variable dyspnea

Cough and sputum

Cough and/or wheeze

None

Present in >50% of

etiology

patients

Treatment response
Corticosteroids

Mildly positive/negative

Positive

Bronchodilators

Partially reversible

Reversible

Smoking status

Usually, history of

Nonsmokers affected

heavy smoking
Airflow

Cannot be normalized;

Can be normalized

limitation

is always reduced;

after resolution of an

(FEV1)

deteriorates with
advancing disease

episode

Notes: Adapted from Am J Med, 117(Suppl12A). Doherty DE. The pathophysiology of
airway dysfunction, 11–23, Copyright (2004), with permission from Elsevier.12
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 second; HLA-DR+, human leukocyte antigen-DR; VLA-1+,
very late activation antigen-1.

wheezing (Table 1).5 Unfortunately, delayed diagnosis is
common and many patients present only after they have
experienced ≥1 exacerbation, often mistakenly labeled as
recurrent bronchitis.17 Early diagnosis and treatment are
essential to improve patients’ lung function, functional sta
tus, and QoL, and to reduce exacerbations.18 COPD can be
detected early on if the clinicians consider COPD as part of
their differential diagnosis. For example, when a patient is
>40 years old and has recurrent acute bronchitis or bad colds
that last for weeks, COPD should be suspected even if the
patient is a nonsmoker. Of note, women are less likely to be

International Journal of Chronic Obstructive Pulmonary Disease 2021:16

suspected of having or diagnosed with COPD than men with
similar symptoms,19 possibly because, COPD traditionally
was considered a “male” disease. However, various factors,
including smoking, have contributed to the rising prevalence
of COPD in women.20 Clinicians can also increase the like
lihood of detecting COPD by asking targeted questions
focused on respiratory symptoms (eg, changes in the ability
to do activities or changes in lifestyle because of shortness of
breath). Patients often attribute these symptoms to being
“old, overweight, or out of shape”. Questions such as “Do
you get or have you ever gotten short of breath when you
climb a flight of stairs or walk up a hill?” are more specific
and easier for patients to answer than a vague question such
as “Do you get short of breath?” Useful tools that are avail
able to identify and assess baseline symptomatology can be
used to monitor changes in severity over time. The modified
Medical Research Council (mMRC) dyspnea scale com
prises five statements that describe a range of dyspnea effects
in increasing order of severity. Use of this questionnaire is
recommended in the GOLD 2020 report5 (Supplementary
Table 1). Although this questionnaire may be helpful for the
initial identification of breathlessness and support evaluation
for COPD,21 it is less useful for monitoring over time
because moving from one grade to the next requires a very
large change in functional abilities. Alternatively, the COPD
Assessment Test (CAT), comprising eight items that are each
scored using a 6-point scale (0–5), is useful in assessing the
symptomatic impact of COPD. A higher CAT score indicates
poorer health. CAT is more sensitive in detecting improve
ments with treatment or a decline of disease progression or
exacerbations (Supplementary Figure 1).5,22 Supplementary
Videos 1 and 2.

COPD Risk Factors
In addition to understanding patients’ symptoms, knowl
edge of COPD risk factors is important. As major risk
factors for COPD, current and past smoking history must
be assessed.5 Nonsmokers exposed to second-hand smoke
in childhood and adult years are also at an increased risk
of developing COPD.23 Cigarette smoking was rated as the
cause of COPD in 50%–70% of patients in developed
countries.24 Genetics also contributes to the risk of devel
oping COPD. In a meta-analysis of genome-wide associa
tion studies, several genetic loci were associated with
COPD pathophysiology.25 Serine protease α1-antitrypsin
deficiency, found in 1%–3% of patients with COPD, is the
most widely reported genetic factor that increases COPD
risk.26 Other COPD risk factors include occupational
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exposure (eg, to dust, vapors, organic materials, fumes,
and chemicals), indoor and outdoor air pollutants (includ
ing biomass fuels), and aging.5

Diagnosis
Diagnosis begins with clinical suspicion, usually in
patients who report shortness of breath with activity.
Overall, symptomatic, at-risk individuals who require
spirometry and evaluation for COPD include those with
recurring respiratory events (eg, acute bronchitis, bad
colds, chronic cough, and excess sputum production), his
tory of risk factors, decrease in activities because of dys
pnea, and/or a family history of COPD.5
Spirometry is essential and required to confirm
a COPD diagnosis.5 It also is useful for tracking treatment
response, potentially adjusting medications, and monitor
ing disease progression. When rapid disease progression is
identified, further evaluation and referral to a lung specia
list are indicated.5 A postbronchodilator (10–15 minutes
after 2–4 puffs of a short-acting bronchodilator) forced
expiratory volume in 1 second (FEV1) to forced vital
capacity (FVC) ratio of <0.70 confirms the presence of
persistent or fixed airflow limitation. FVC is the maximal
volume of air that can be forcibly exhaled after taking in
the deepest breath possible, and FEV1 is the maximal
volume of air exhaled in the first second during an FVC
maneuver (Figure 2).5
Despite recommendations, spirometry is not regularly
used in clinical practice.27 Underuse of spirometry in pri
mary care settings is attributed to uncertainty about the
benefit of COPD diagnosis, lack of time and resources,
unfamiliarity with the technique, and/or difficulty in inter
preting results.28,29 However, spirometry is required to con
firm a COPD diagnosis, can be performed in primary care
practice using an office-based system,30 and is a billable
procedure reimbursed by payors. Although patients can be
referred to specialists and hospitals for spirometry, followthrough may be limited; therefore, spirometry can and
should be done in primary care offices.31

Assessment of Airflow Limitation
Severity, Symptoms, and Exacerbation
Frequency
Once a COPD diagnosis is confirmed, spirometry findings can
also be used to determine the severity of airflow limitations
(Figure 2), which is based on the patient’s FEV1 relative to
normal values.5 However, treatment decisions are based on
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symptoms and history of exacerbations treated at home and in
the hospital. Per the GOLD 2019 report, symptom burden and
exacerbation frequency in the prior year are used to categorize
patients into GOLD group A (few symptoms and 0–1 exacer
bations not leading to hospitalization), group B (more symp
toms and 0–1 exacerbations not leading to hospitalization),
group C (few symptoms but ≥2 exacerbations or ≥1 exacerba
tion leading to hospitalization), or group D (more symptoms
and ≥2 exacerbations or ≥1 exacerbation leading to hospitaliza
tion) to guide initial pharmacological therapy (Figure 2).5

Treatment of COPD
After categorizing a patient as belonging to GOLD group
A, B, C, or D, the GOLD treatment algorithm (Figure 2)
can be used to determine appropriate initial pharmacolo
gical treatment, which should be complemented with non
pharmacological approaches as appropriate.

Pharmacological Interventions
Bronchodilators—the first-choice pharmacotherapy for COPD
across all patient groups—increase airway diameter and decrease
air trapping, thereby improving airflow and reducing dyspnea.5
GOLD group A patients should be offered a bronchodilator (shortor long-acting), if symptoms are present. A long-acting muscarinic
antagonist (LAMA) or a long-acting β2-agonist (LABA) is sug
gested as initial treatment for GOLD group B patients, and—
because of their complementary mechanisms of action—dual
bronchodilator therapy with a LAMA and a LABA can be con
sidered for highly symptomatic (CAT score ≥20) patients. LAMA
monotherapy improves lung function and reduces exacerbations
and is suggested for initial pharmacological treatment in GOLD
group C (Figure 2). While initial therapy with LAMA is recom
mended for group GOLD group D patients, starting with a LAMA
+LABA combination may be more appropriate because many of
these patients are highly symptomatic (eg, CAT >20). Although
commonly used as monotherapy for asthma control, inhaled corti
costeroids (ICS) are not approved worldwide for use as mono
therapy in COPD patients of any severity. Long-term ICS use is
associated with safety concerns such as an increased risk of
pneumonia, active tuberculosis, and osteoporosis.32 However,
LABA+ICS may be the first-choice treatment in COPD GOLD
group D patients with a history of asthma or blood eosinophil
counts ≥300 cells/μL.5 Once recommended initial therapy is
implemented, patients should be reassessed for treatment response.
According to recommendations in the GOLD 2020 report, if
response to initial therapy is not appropriate, follow-up treatment
based on the patients’ symptoms and exacerbations—and not on
their initial GOLD group classification—should be provided
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Figure 2 Diagnosis, assessment, initial, and follow-up treatment of COPD.
Notes: Reproduced with permission from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis, and Management of Chronic
Obstructive Pulmonary Disease. 2020. https://goldcopd.org.5
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity;
GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC,
modified Medical Research Council dyspnea scale.
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(Figure 2). Separate treatment algorithms are provided based on
the need to treat dyspnea or prevent exacerbations.
For patients with persistent breathlessness or exercise
limitation despite long-acting bronchodilator monotherapy,5
step-up to a LAMA+LABA is recommended. If dual bronch
odilator therapy does not improve symptoms, step down to
monotherapy, or switching inhalers or molecules are recom
mended. When patients experience persistent breathlessness
or exercise limitation despite LABA+ICS therapy, triple
therapy with a LAMA+LABA+ICS may be considered.
However, if ICS was inappropriately indicated to treat
patients without a history of exacerbations, caused side
effects, or did not yield any response, switching to
a LAMA+LABA is recommended.
For patients who continue to experience exacerbations
despite long-acting bronchodilator monotherapy, step-up to
a LAMA+LABA or LABA+ICS (in patients with a history
of hospitalizations for COPD exacerbations, with ≥2
moderate COPD exacerbations per year, eosinophil counts
>300 cells/μL, or a history of asthma) is recommended.5 For
patients who continue to exacerbate despite maximal LAMA
+LABA, triple therapy is recommended if eosinophil counts
≥100 cells/μL and roflumilast or azithromycin is recom
mended if eosinophil counts <100 cells/μL.
While ICS therapy has a role in COPD management, there
may be a current over-use based on the GOLD 2020 treatment
algorithms.33 In 2019, some of the recommendations sur
rounding the use of ICS in GOLD were changed due to
concerns of over-use of ICS, but these recommendations
were revised in 2020 to reflect the importance of ICS in certain
circumstances, such as hospitalization for exacerbation.
Whether, when, and how non-recommended ICS treatment
can be withdrawn safely should be considered, particularly in
patients who had ICS initiated despite no or infrequent exacer
bations, especially if they also have low eosinophil counts. In
the INSTEAD trial,34 non-exacerbating patients with moder
ate COPD were switched from salmeterol+fluticasone (a
LABA+ICS) to indacaterol (a LABA) without a significant
change in exacerbation rate. Patients in this trial were at low
risk of exacerbations and should not have been prescribed ICS
based on the GOLD 2020 treatment algorithm. Similarly,
withdrawal of ICS did not increase exacerbation rates in the
WISDOM35 and SUNSET36 trials, which included patients
with severe/very severe and moderate-to-severe COPD,
respectively.
To avoid potentially difficult decisions regarding step
ping down treatment, ICS should be initiated only when
recommended, and not in patients with no or infrequent
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exacerbations or in patients whose exacerbations can be
controlled with dual bronchodilator therapy.
In addition to deciding on appropriate initial and mainte
nance medications, COPD clinicians should also consider
which inhaler is optimal for each patient. Prescribing an inha
ler based on patient characteristics and preferences, and train
ing patients on correct inhaler use, will lead to better
adherence.5 During follow-up, inhaler technique and adher
ence should be assessed. If not optimal, switching to
a different inhaler device may be considered.5

Nonpharmacological Interventions
Pharmacological therapy for COPD should be complemen
ted with nonpharmacological approaches, including beha
vioral therapies and pulmonary rehabilitation, as
appropriate. Assessment of smoking history and initiation
of a cessation program, if necessary, must be a part of all
COPD patients’ treatment plans. Because relapses are com
mon, smoking status and second-hand smoke exposure
should be continually monitored over time. Reinforcement
to remain a sustained quitter or encouragement to stop smok
ing should be given at each opportunity.
Other nonpharmacological approaches at diagnosis, based
on GOLD 2020, include referring GOLD group A-D patients
to pulmonary rehabilitation including exercise training, pro
moting physical activity, encouraging adherence to the pre
scribed medication, and prescribing vaccinations.5
Recommendations for nonpharmacological management of
COPD at diagnosis and during follow-up are summarized in
Figure 3. Teaching COPD patients breathing techniques aimed
at improving respiratory muscle strength and decreasing air
trapping in the lungs, which can reduce the sense of dyspnea is
also beneficial.5 Pursed-lip breathing, which reduces heigh
tened air trapping by a mechanical maneuver, is a practical and
simple technique that can be taught quickly and can make
a substantial difference to patients (Supplementary Figure 2).
Pulmonary rehabilitation improves symptoms, reduces hospi
tal readmissions, increases activity levels, and decreases levels
of anxiety and depression.5,37 Although programs can be diffi
cult to implement in some areas, largely because of low reim
bursement rates, pulmonary rehabilitation is one of the single
best treatments for patients with COPD.37 Exercise programs,
disease education, and setting activity goals for patients can be
helpful when pulmonary rehabilitation is not available.5
Finally, ensuring that patients with COPD receive all indicated
immunizations (eg, influenza, pneumococcal pneumonia,5
Tdap, and Zoster) is important to overall patient care and
may help to reduce exacerbations and other poor outcomes.
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Figure 3 Nonpharmacological management of COPD at diagnosis and follow-up.
Notes: Reproduced with permission from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis, and Management of Chronic
Obstructive Pulmonary Disease. 2020. https://goldcopd.org.5
Abbreviation: Flu, influenza.

Referral to a pulmonologist may be considered at diag
nosis, at discharge after hospitalization for an exacerba
tion, or when symptoms progressively deteriorate.5

Chronic Disease Management
Chronic disease management involves regular evaluation to
monitor disease progression and treatment response. For
COPD, important aspects include monitoring symptom bur
den and exacerbation frequency, reviewing and observing
device/inhaler technique, reviewing medication adherence,
and updating any action plans. But, patient evaluation and
treatment are a continuous process and cannot be accom
plished in a single visit. A COPD action plan should be

International Journal of Chronic Obstructive Pulmonary Disease 2021:16

developed and individualized for each patient; however,
development is often not logical or feasible until the second
or third visit. The COPDF action plan,38 which was designed
to improve communication between clinicians and patients
with COPD, and to encourage disease self-management,
should be considered (Supplementary Figure 3). Further,
while these regular evaluations are essential to achieve opti
mal treatment outcomes, evidence indicates clinicians and
patients do not necessarily appreciate their importance. For
example, according to results of quantitative, web-based,
descriptive, cross-sectional surveys of clinicians and patients
with COPD in the United States, both groups had limited
concerns about proper device use.39 Less than half of the
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clinicians surveyed reported assessing device technique in
every newly diagnosed patient, and many reported not routi
nely assessing and inconsistently educating about proper
device use. Not surprisingly, incorrect inhaler use led to
poor clinical outcomes.
Patient education is important in ensuring successful disease
management and optimal medication adherence and compliance.
Regular demonstrations and direct observations of patients’ use
of their medication delivery systems should be done at each visit

to ensure proper use. In addition, patients should be reminded
that although serious, COPD symptom burden and progression
may be modifiable with treatment and behavioral changes.
As mentioned, an important aspect of patient education
is smoking cessation.40 Motivating current smokers with
COPD to quit may be particularly challenging because
they continue to smoke despite disease symptoms. “Lung
age” may be a useful tool to demonstrate the effects of
cigarette smoking and is known to increase smoking

Figure 4 Effects of smoking on COPD risk and lung age.
Notes: Adapted with permission from Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648, Copyright© 1977
BMJ Publishing Group Ltd.41 COPD risk and smoking cessation:41,42 effects of smoking and smoking cessation on FEV1 in patients who are likely to develop COPD if
they smoke are illustrated by solid lines. The graphs represent cross-sectional data from several individuals measured at different time points. Although the rate of
loss of FEV1 for a susceptible smoker is shown, others may experience different rates of loss, and reach “disability” at different ages. While the underlying cause of
“Death” is irreversible COPD, the immediate cause may be pneumonia, cor pulmonale, respiratory failure, or aggravation of heart disease by respiratory insufficiency.
Adapted from Doherty DE. A review of the role of FEV1 in the COPD paradigm. COPD. 2008;5(5):310–318, Copyright© 2008. Taylor and Francis.42 Lung age:42
Nonsmokers or smokers who are not susceptible to the effects of tobacco smoke experience a normal decline in lung function (blue line). Susceptible smokers
experience an accelerated loss of lung function over time (orange line). For example, if the FEV1 of a susceptible 40-year-old smoker (measured at 75% predicted;
dotted vertical line) is extrapolated (horizontal line drawn to the curve of a nonsmoker/non-susceptible smoker), the “Lung Age” is approximately 74 years, suggesting
that the lung function is equivalent to that of a nonsmoker/non-susceptible smoker at 74 years.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
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cessation rates.40 In addition, spirometry curves (Figure 4)
are helpful in demonstrating that quitting smoking even at
a late age can reduce morbidity and mortality.40–42
Ensuring continuity of care over time is central to
chronic disease management programs, including those for
COPD. During repeated visits, clinicians must confirm that
patients are prescribed and are taking appropriate COPD
maintenance therapy, addressing smoking cessation, offered
support for an increased activity or pulmonary rehabilita
tion, and considered as candidates for palliative (not just
end-of-life) care. All of these activities are especially impor
tant following any hospital admission for an exacerbation.

Conclusions
COPD is a leading cause of morbidity and mortality in the
United States. Because most patients with COPD are mana
ged in the primary care setting, primary care clinicians play
a pivotal role in appropriately managing COPD. Following
up-to-date treatment recommendations such as those pro
vided in the GOLD 2020 strategy report, engaging in chronic
disease management, and investing in patient education are
important to achieve the greatest benefits of COPD treatment.
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